Vir Biotechnology Inc. (VIR) Misses Q4 EPS by 41c

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.76), $0.41 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $49.4 million versus the consensus estimate of $149.6 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand
• BMO starts chip stocks coverage: Here are its preferred picks